Is non-insulin dependent glucose uptake a therapeutic alternative? Part 1: Physiology, mechanisms and role of non insulin-dependent glucose uptake in type 2 diabetes

Diabetes and Metabolism

Volumn 31, Issue 5, 2005, Pages 415-426

  Wiernsperger, N F ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

AMPK; Glucokinase; Glucose transporter; Nitric oxide; Non insulin dependent glucose transport; Type 2 diabetes

Indexed keywords

ADIPONECTIN; AZIDE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOGEN; GLYCOGEN SYNTHASE; INSULIN RECEPTOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYRICETIN; NEU DIFFERENTIATION FACTOR; NITRIC OXIDE; PARATHYROID HORMONE; PROTEIN KINASE B; PROTEIN KINASE C; SHIKONIN; SOMATOMEDIN C; XYLOSE;

BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE FLUIDITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ERYTHROCYTE; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPOXIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE PHOSPHORYLATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 27844554767     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70212-4     Document Type: Review

References (187)

1. Turner RC. The UK Prospective Diabetes Study. A review. Diabetes Care 1998;21(Suppl 3):C35-8
2. Yosefy C. Hyperglycaemia and its relations to cardiovascular morbidity and mortality: has it been resolved? Acta Diabetol 2003;40:S380-8
3. The Writing Team for DCCT. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9
4. Yki-Järvinen H. Management of type 2 diabetes mellitus and cardiovascular risk. Drugs 2000;60:975-83
5. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1-10
6. Reasner CA, Göke B. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Br J Diabetes Vase Dis 2002;2:290-5
7. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
8. Reusch JEB. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose. J Clin Invest 2003;112:986-8
9. Gould MK, Chaudry IH. The action of insulin on glucose uptake by isolated rat soleus muscle. II. Dissociation of a priming effect of insulin from its stimulatory effect. Biochim Biophys Acta 1970;215:258-263
10. Yoa RG, Rapin JR, Wiernsperger NF, Martinand A, Belleville I. Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin. Clin Exp Pharmacol Physiol 1993;20:563-7
11. Thomas CR, Turner SL, Jefferson WH, Bailey CJ. Prevention of dexamethasone-induced insulin resistance by metformin. Biochem Pharmacol 1998;56:1145-50
12. Nelson R, Spann D, Elliott D, et al. Evaluation of the oral anti hyperglycaemic drug metformin in normal and diabetic cats. J Vet Intern Med 2004;18:18-24
13. Suh K, Song YM, Murata C, Joyce M, Ditzler TM, Henry RR. Role of basal insulin in maintenance of intracellular glucose metabolic pathways in non-insulin-dependent diabetes mellitus. Metabolism 1995;44:41-6
14. Del Prato S, Riccio A, Vigili de Kreutzenberg S, Dorella M, Tiengo A, De Fronzo RA. Basal plasma insulin levels exert a qualitative but not quantitative effect on glucose-mediated glucose uptake. Am J Physiol 1995;268:E1089-95
15. Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R. Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 2002;283:E275-83
16. Holloszy JO, Hansen PA. Regulation of glucose transport into skeletal muscle. Rev Physiol Biochem Pharmacol 1996;128:100-93
17. Lavelle-Jones M, Scott MH, Kolterman O, Moossa AR, Olefsky JM. Non-insulin-mediated glucose uptake predominates in postabsorptive dogs. Am J Physiol 1987;252:E660-6
18. Baron AD, Kolterman OG, Bell J, Mandarino LJ, Olefsky JM. Rates of non insulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest 1985;76:1782-8
19. Forbes A, Elliott T, Tildesley H, Finegood D, Meneilly GS. Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes 1998;47:1915-9
20. García-Estévez DA, Araujo-Vilar D, Cabezas-Cerrato J. Non-insulin-mediated glucose uptake in several insulin-resistant states in the post-absorptive period. Diabetes Res Clin Pract 1998;39:107-13
21. Bistritzer T, Roeder LM, Hanukoglu L, Levin PA. Non-insulin dependent diabetic patients have increased glucose uptake in red blood cells. Horm Metab Res 1991;23:70-3
22. Hu XJ, Peng F, Zhou HQ, Zhang ZH, Cheng WY, Feng HF. The abnormality of glucose transporter in the erythrocyte membrane of Chinese type 2 diabetic patients. Biochim Biophys Acta 2000;1466:306-14
23. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 1996;19:1018-30
24. Ader M, Ni TC, Bergman RN. Glucose effectiveness assessed under dynamic and steady state conditions. Comparability of uptake versus production components. J Clin Invest 1997;99:1187-99
25. Basu A, Rizza RA. Glucose effectiveness: measurement in diabetic and nondiabetic humans. Exp Clin Endocrinol Diabetes 2001;109:8157-65
26. Stumvoll M, Tataranni PA, Bogardus C. The role of glucose allostasis in type 2 diabetes. Rev Endocr Metab Disord 2004;5:99-103
27. Lang CH. Rates and tissue sites of non insulin - and insulin - mediated glucose uptake in diabetic rats. Proc Soc Exp Biol Med 1992;199:81-7
28. Pacini G, Thomaseth K, Ahrén B. Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. Am J Physiol Endocrinol Metab 2001;281:E693-703
29. Bonadonna RC. Alterations of glucose metabolism in type 2 diabetes mellitus. An overview. Rev Endocr Metab Disord 2004;5:89-97
30. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 1984;73:664-72
31. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Diabetes 1998;47:1735-47
32. Ahrén B, Pacini G. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. Am J Physiol Endocrinol Metab 2002;283:E738-44
33. Hawkins M, Tonelh J, Kishore P, et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes 2003;52:2748-58
34. Richey JM, Freed HS, Bergman RN. Lack of compensation for insulin resistance by insulin secretion or glucose effectiveness in fat fed rats. Diabetes 2002;51(Suppl 2):2326 (abstract)
35. Capaldo B, Santoro D, Riccardi G, Perrotti N, Saccà L. Direct evidence for a stimulatory effect of hyperglycemias per se on peripheral glucose disposal in type II diabetes. J Clin Invest 1986;77:1285-90
36. Soskin S, Levine R. A relationship between blood sugar level and the rate of sugar utilization, effecting the theories of diabetes. Am J Physiol 1937;120:761-70
37. Mäkimattila S, Virkamäki A, Malmström R, Utriainen T, Yvi-Jarvinen Y. Insulin resistance in type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab, 1996;81:707-12
38. Zierath JR, HE L, Guma A, et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996;39:1180-9
39. Yki-Järvinen H, Mäkimattila S. Insulin resistance due to hyperglycaemia: an adaptation protecting insulin-sensitive tissues. Diabetologia 1997;40:S141-4
40. Mitrakou A, Vuorinen-Markkola H, Raptis G, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992;75:379-82
41. Kelley DE, Mandarino LJ. Hyperglycaemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in non insulin-dependent diabetes mellitus. J Clin Invest 1990;86:1999-2007
42. 2+ -dependent mechanism. Diabetes 1995;44:1345-8
43. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 1998;102:744-53
44. Farrace S, Rossetti L. Hyperglycemia markedly enhances skeletal muscle glycogen synthase activity in diabetic, but not in normal conscious rats. Diabetes 1992;41:1453-63
45. Alzaid AA, Dinneen SF, Turk DJ, Caumo A, Cobelli C, Rizza RA. Assessment of insulin action and glucose effectiveness in diabetic and non diabetic humans. J Clin Invest 1994;94:2341-8
46. Henriksen JE, Alford F, Handberg A, et al. Increased glucose effectiveness in normoglycemic but insulin-resistant relatives of patients with non-insulin-dependent diabetes mellitus. A novel compensatory mechanism. J Clin Invest 1994;94:1196-1204
47. Del Prato S, Matsuda M, Simonson DC, et al. Studies on the mass actino effect of glucose in NIDDM and IDDM:evidence for glucose resistance. Diabetologia 1997;40:687-97
48. Nagasaka S, Tokuyama K, Kusaka I, et al. Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stable-labeled minimal model approach. Diabetes 1999;48:1054-60
49. Hawkins M, Gabriely I, Wozniak R, Reddy K, Rossetti L, Shamoon H. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes 2002;51:2179-89
50. Martin B, Warram JH, Krolewski A, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-9
51. 12 myotubes and rat skeletal muscle. Diabetes 1995;44:646-50
52. Aas V, Torbla S, Andersen MH, Jensen J, Rustan AC. Electrical stimulation improves insulin responses in a human skeletal muscle cell model of hyperglycemia. Ann NY Acad Sci 2002;967:506-15
53. Sargeant R, Mitsumoto Y, Sarabia V, Shillabeer G, Klip A. Hormonal regulation of glucose transporters in muscle cells in culture. J Endocrinol Invest 1993;16:147-62
54. El Kebbi IM, Roser S, Pollet RJ, Cushman SW, Wilson CM. Regulation of the GLUT1 glucose transporter in cultured myocytes: total number and subcellular distribution as determined by photaffinity labeling. Biochem J 1994;301:35-40
55. Dimitrakoudis D, Ramlal T, Rastogi S, Vranic M, Klip A. Glycaemia regulates the glucose transporter number in the plasma membrane of rat skeletal muscle. Biochem J 1992;284:341-8
56. Buren J, Lindmark S, Renstrom F, Erikkson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism 2003;52:239-45
57. Rossetti L, Laughlin MR. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 1989;84:892-9
58. Beck-Nielsen H, Hother-Nielsen O, Staehr P. Is hepatic glucose production increased in type 2 diabetes mellitus? Curr Diab Rep 2002; 2:231-6
59. Kawano Y, Rincon J, Soler A, Ryder JW, Nolte LA, Zierath JR, Wallberg-Henriksson H. Changes in glucose transport and protein kinase Cq2 in rat skeletal muscle induced by hyperglycaemia. Diabetologia 1999;42:071-9
60. Caruso M, Miel C, Oriente F, et al. In L6 skeletal muscle cells, glucose induces cytosolic translocation of protein kinase C-β and trans-activates the insulin receptor kinase. J Biol Chem 1999;274:28637-44
61. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H. Increased glucose uptake promotes oxidative stress and PKC-q activation in adipocytes of obeses, insulin-resistant mice. Am J Physiol Endocrinol Metab 2003;285:E295-302
62. Han DH, Chen MM, Holloszy JO. Glucosamine and glucose induce insulin resistance by different mechanisms in rat skeletal muscle. Am J Physiol Endocrinol Metab 2003;285:E1267-72
63. Pratt SE, Colby-Germinario S, Manuel S, Germinario RJ. Evidence that modulation of glucose transporter intrinsic activity is the mechanism involved in the allose-mediated depression of hexose transport in mammalian cells. J Cell Physiol 1994;161:580-8
64. Vannucci SJ, Nishimura H, Satoh S, Cushman SW, Holman GD, Simpson IA. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Biochem J 1992;288:325-30
65. Shi Y, Liu H, Vanderburg G, Samuel SJ, Ismail-Beigi F, Jung CY. Modulation of GLUT1 intrinsic activity in Clone 9 cells by inhibition of oxidative phosphorylation. J Biol Chem 1995;270:21772-8
66. Zhang JZ, Abbud W, Prohaska R, Ismail-Beigi F. Overexpression of stomatin depresses GLUT-1 glucose transporter activity. Am J Physiol Cell Physiol 2001;280:C1277-83
67. Dauterive R, Laroux S, Bunn RC, Chaisson A, Sanson T, Reed BC. C-terminal mutations that alter the turnover number for 3-O-methylglucose transport by GLUT1 an GLUT4. J Biol Chem 1996; 271:11414-21
68. Diamond DL, Carruthers A. Metabolic control of sugar transport by derexpression of cell surface glucose transporters. J Biol Chem 1993; 268:6437-44
69. Clancy BM, Harrison SA, Buxton JM, Czech MP. Protein synthesis inhibitors activate glucose transport without increasing plasma membrane glucose transporters in 3T3-L1 adipocytes. J Biol Chem 1991; 266:10122-30
70. Smith R, Tiesinga JJ, Shah N, et al. Genistein inhibits insulin-stimulated glucose transport and decreases immunocytochemical labelling of GLUT4 carboxyl terminus without affecting translocation of GLUT4 in isolated rat adipocytes: additional evidence of GLUT4 activation by insulin. Arch Biochem Biophys 1993;300:238-46
71. Pilch PF, Thompson PA, Czech MP. Coordinate modulation of D-glucose transport activity and bilayer fluidity in plasma membranes derived form control and insulin-treated adipocytes. Proc Natl Acad Sci USA 1980;77:915-8
72. Ong KC, Khoo HE. Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Biochem Pharmacol 1996;51:423-9
73. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 1999;25:110-27
74. Barnes K, Ingram JC, Bennett MDM, Stewart GW, Baldwin SA. Methyl-b-cyclodextrin stimulates glucose uptake in Clone 9 cells: a possible role for lipid rafts. Biochem J 2004;378:343-51
75. Rubin D, Ismail-Beigi F. Distribution of Glut1 in detergent-resistant membranes (DRMs) and non-DRM domains: effects of treatment with azide. Am J Physiol Cell Physiol 2003;285:C377-83
76. Czech MP, Clancy BM, Pessino A, Woon CW, Harrison SA. Complex regulation of simple sugar transport in insulin-responsive cells. Trends Biochem Sci 1992;17:197-201
77. Bunn RC, Jensen MA, Reed BC. Protein interactions with the glucose transporter binding protein GLUT1CBP that provide a link between GLUT1 and the cytoskeleton. Mol Biol Cell 1999;10:819-32
78. Abumrad NA, Briscoe P, Beth AH, Whitesell RR. Temperature dependence of glucose transport in erythrocyte from normal and alloxan-diabetic rats. Biochim Biophys Acta 1988;938:222-30
79. Levine KB, Cloherty EK, Fidyk NJ, Carruthers A. Structural and physiologic determinants of human erythrocyte sugar transport regulation by adenosine triphosphate. Biochemistry 1998;37:12221-32
80. Hamrahian AH, Zhang JZ, Elkhairi FS, Prasad R, Ismail-Beigi F. Activation of GLUT1 glucose transporter in response to inhibition of oxidative phosphorylation. Arch Biochem Biophys 1999;368:375-9
81. Abbott RE, Schachter D. Topography and functions of sulfhydryl groups of the human erythrocyte glucose transport mechanism. Mol Cell Biochem 1988;82:85-90
82. Kasahara T, Kasahara M. Characterization of rat Glut4 glucose transporter expressed in the yeast Saccharomyces cerevisiae: comparison with GLUT1 glucose transporter. Biochim Biophys Acta 1997; 1324:111-9
83. Hofman M, Mainka P, Tritschler H, Fuchs J, Zimmer G. Decrease of red cell membrane fluidity and - SH groups due to hyperglycemic conditions is counteracted by q-lipoic acid. Arch Biochem Biophys 1995;324:85-92
84. Freisleben HJ, Furstenberger HJ, Deisinegr S, et al. Interaction of glucose and metformin with isolated red cell membrane. Arzneim-Forsch/Drug Res 1996;46:773-8
85. Muller S, Denet S, Candiloros H, et al. Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur J Pharmacol 1997; 337:103-10
86. Garcia JC, Strube M, Leingang K, Keller K, Mueckler MM. Amino acid substitutions at tryptophan 388 and tryptophan 412 of the HepG2 (Glut1) glucose transporter inhibit transport activity and targeting to the plasma membrane in Xenopus Oocytes. J Biol Chem 1992;267:7770-6
87. Mesmer OT, Lu Z, Xia L, Lo TC. Effects of 2-deoxy-d-glucose on the functional state of the rat myoblast GLUT 1 transporter. Biochem Mol Biol Int 1996;40:217-33
88. Asano T, Takata K, Katagiri H, et al. The role of N-glycosylation in the targeting and stability of GLUT1 glucose transporter. FEBS Lett 1993;324:258-61
89. Furtado LM, Poon V, Klip A. GLUT4 activation: thoughts on possible mechanisms. Acta Physiol Scand 2003;178:287-96
90. Sweeney G, Somwar R, Ramlal T, Volchuk A, Ueyama A, Klip A. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. J Biol Chem 1999;274:10171-8
91. Somwar R, Perreault M, Kapur S. Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle. Potential role in the stimulation of glucose transport. Diabetes 2000;49:1794-800
92. Tardif A, Julien N, Chiasson JL, Coderre L. Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation. Am J Physiol Endocrinol Metab 2003;284:E1055-64
93. Furtado LM, Somwar R, Sweeney G, et al. Activation of the glucose transporter GLUT4 by insulin. Biochem Cell Biol 2002;80:569-78
94. Bazuine M, Ouwens DM, Gomes de Mesquita DS, Maassen JA. Arsenite stimulated glucose transport in 3T3-L1 adipocytes involves both GLUT4 translocation and p38 MAPK activity. Eur J Biochem 2003; 270:3891-903
95. Baldwin SA, Barrost LF, Griffiths M, et al. Regulation of GLUT1 in response to cellular stress. Biochem Soc Trans 1997;25:954-8
96. Lemieux K, Konrad D, Klip A, Marette A. The AMP-activated protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases alpha and beta in skeletal muscle. FASEB J 2003;17:1658-65
97. Kumar N, Dey S. Metformin enhances insulin signaling in insulin-dependent and independent pathways in insulin resistant muscle cells. B J Pharmacol 2002;137:329-36
98. Tong H, Chen W, London RE, Murphy E, Steenbergen C. Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol -kinase. J Biol Chem 2000;275:11981-6
99. Oh D, Ciaraldi TP, Sathyaprakash R, et al. p38 MAPK expression and phosphorylation in human tissues: modulation by insulin, obesity and type 2 diabetes. Diabetes 2003;52(Suppl 1):222
100. Karnieli E, Moscona R, Rafaeloff R, Illouz YG, Armoni M. Discrepancy between glucose transport and transporters in human femoral adipocytes. Am J Physiol 1989;256:E179-85
101. Abel ED, Shepherd PR, Kahn BB. Glucose transporters and pathophysiologic states. In: LeRoith D, Taylor SI, Olefsky JM Eds. Diabetes Mellitus 1996;59:530-43
102. Shetty M, Kuruvilla AK, Ismail-Beigi F, Loeb JN. Stimulation of glucose transport in Clone 9 cells by insulin and thyroid hormone: role of GLUT1 activation. Biochim Biophys Acta 1996;1314:140-6
103. Baly DL, Horuk R. Dissociation of insulin-stimulated glucose transport form the translocation of glucose carriers in rat adipose cells. J Biol Chem 1987;262:21-4
104. Goodyear LJ, Hirshman MF, Smith RJ, Horton ES. Glucose transporter number, activity, and isoform content in plasma membranes of red and white skeletal muscle. Am J Physiol 1991;261:E556-61
105. Karnieli E, Garvey WT, Olefsky JM, et al. Potential role for insulin and cycloheximide in regulating the intrinsic activity of glucose transporters in isolated rat adipocytes. Endocrinology 1993;6:2943-50
106. Zipper H, Mawe RC. The exchange and maximal net flux of glucose across the human erythrocyte. The effect of insulin, insulin derivatives and small proteins. Biochim Biophys Acta 1972;282:311-25
107. Dustin ML, Jacobson GR, Peterson SW. Effects of insulin receptor down-regulation on hexose transport in human erythrocytes. J Biol Chem 1984;259:13660-3
108. Abbud W, Habinowski S, Zhang JZ, et al. Stimulation of AMP-Activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 2000;380: 347-52
109. Kuroda M, Honnor RC, Cushman SW, Londos C, Simpson IA. Regulation of insulin-stimulated glucose transport in the isolated rat adipocyte. J Biol Chem 1987;262:245-53
110. Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with plasma intact parthyroid hormone level. Metabolism 2000;49:1501-5
111. Detaille D, Wiernsperger N, Devos P. Metformin interaction with insulin-regulated glucose uptake, using the Xenopus laevis oocyte model expressing the mammalian transporter GLUT4. Eur J Pharmacol 1999;377:127-36
112. 2+ -induced inhibition of insulin-stimulated glucose transport. J Biol Chem 1993; 268:3352-6
113. Harrison SA, Buxton JM, Czech MP. Suppressed intrinsic catalytic activity of GLUT1 glucose transporters in insulin-sensitive 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1991;88:7839-43
114. Hansen PA, Wang W, Marshall BA, Holloszy JO, Mueckler M. Dissociation of GLUT4 translocation and insulin-stimulated glucose transport in transgenic mice overexpressing GLUT1 in skeletal muscle. J Biol Chem 1998;273:18173-9
115. Comi RJ, Hamilton H. Reduction of red cell glucose transporter intrinsic activity in diabetes running. Horm Metab Res 1994;26:26-32
116. Napoli R, Hirshman MF, Horton ES. Mechanisms and time course of impaired skeletal muscle glucose transport activity in streptozotocin diabetic rats. J Clin Invest 1995;96:427-37
117. Rizk NM, Meier DA, Krakower GR, Kissebah AH. Mechanisms of insulin-resistant glucose utilization in rat skeletal muscle. Mol Genet Metab 1998;63:126-33
118. Rosholt M, King P, Horton E, et al. High-fat diet reduces glucose transporter responses to both insulin and exercise. Am J Physiol 1994; 266:R95-101
119. Brozinick JT, Etgen GJ, Yaspelkis BB, Ivy JL. Glucose uptake and GLUT4 protein distribution in skeletal muscle of the obese Zucker rat. Am J Physiol 1994;267:R236-43
120. Huang C, Somwar R, Patel N, Niu W, Török D, Klip A. Sustained exposure of L6 myotubes to high glucose and insulin decreases insulin-stimulated GLUT4 translocation but upregulates GLUT4 reactivity. Diabetes 2002;51:2090-8
121. Bevan AP, Drake PG, Yale JF, et al. Peroxovanadium compounds: biological actions and mechanism of insulin-mimetics. Mol Cell Biochem 1995;153:49-58
122. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus effects. Mol Cell Biochem 1998;182:109-19
123. Kawa JM, Przybylski R, Taylor CG. Urinary chiro-inositol and myoinositol excretion is elevated in the diabetic db/db mouse and streptozotocin diabetic rat. Exp Biol Med 2003;228:907-14
124. Kellerer M, Machicao F, Berti L, et al. Inositol phospho-oligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. Biochem J 1993;295:699-704
125. Kessler A, Müller G, Wied S, Crecelius A, Eckel J. Signalling pathways of an insulin-mimetic phosphoinositolglycan-peptide in muscle and adipose tissue. Biochem J 1998;330:277-86
126. Kunjara S, Wang DY, Greenbaum AL, McLean P, Kurtz A, Rademacher TW. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes. Mol Genet Metab 1999;68:488-502
127. Müller G, Jung C, Wied S, Weite S, Jordan H, Frick W. Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol Cell Biol 2001;21:4553-67
128. Larner J. D-chiro-inositol- 1st functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3:47-60
129. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of D-chiroinositol-containing inositolphosphoglycan mediator in women, with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242-9
130. Kishi K, Muromoto N, Nakaya Y, Miyata I, Hagi A, Hayashi H, Ebina Y. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 1998;47:550-8
131. Taguchi T, Kishikawa H, Motoshima H, et al. Involvement of bradykinin in acute exercise-induced increase of glucose uptake and GLUT4 translocation in skeletal muscle: studies in normal and diabetic humans and rats. Metabolism 2000;49:920-30
132. Sasson S, Gruzman A, Alpert E, Katzhendler Y, Cerasi E. Development of novel compounds that stimulate glucose transport in a non-insulin dependent manner. [Abstract]. Diabetologia 2003;46 (Suppl):2354
133. Cantó C, Suárez E, Lizcano JM, et al. Neuregulin signaling on glucose transport in muscle cells. JBC 2004;279:12260-8
134. Kamei R, Kitagawa Y, Kadokura M, et al. Shikonin stimulates glucose uptake in 3T3-L1 adipocytes via an insulin-independent tyrosine kinase pathway. Biochem Biophys Res Comm 2002;292:642-51
135. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144:5179-83
136. Winder WW. AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes Technol Ther 2000;2:441-8
137. Wojtaszewski JFP, Jorgensen SR, Hellsten Y, et al. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 2002;51:284-29
138. Ai H, Ihlemann J, Hellstein Y, Lauritzen HP, et al, effect of fiber type and nutritional state on AICAR-and contraction-stimulated glucose transport in rat muscle. Am J Physiol Endocrinol Metab 2002; 282:E1291-300
139. Halse R, Fryer LGD, McCormack JG, Carling D, Yeaman SJ. Regulation of glycogen synthase by glucose and glycogen. A possible role for AMP-activated protein kinase. Diabetes 2003;52:9-15
140. Musi N, Goodyear LJ. AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 2003;178:337-45
141. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinas. Nat Med 2002;8:1288-95
142. Buhl ES, Jessen N, Pold R, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002;51: 2199-206
143. Barnes K, Ingram JC, Porras OH, et al. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 2002;115:2433-42
144. Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002;51:2420-5
145. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-81
146. Wiernsperger NF, Rapin JR, Metformin-insulin interactions: from organ to cell. Diabetes Metab Rev 1995;11:S3-12
147. Hojlund K, Mustard KJ, Staehr P, et al. AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. Am J Physiol Endocrinol Metab 2003;286: E239-44
148. Salt IP, Connell JMC, Gould GW. 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 2000;49:1649-56
149. Kefas BA, Cai Y, Ling Z, et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 2003;30:151-61
150. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997;82:359-63
151. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 2001;50: 241-7
152. Young ME, Radda GK, Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 1997;322:223-8
153. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol 1998;274:E692-9
154. Shearer J, Fueger PT, Vorndick B, et al. AMPkinase-induced skeletal muscle glucose but not long-chain fatty acid uptake is dependent on nitric oxide. Diabetes 2004;53:1429-35
155. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001;7:1138-43
156. Bergandi I, Sivagno F, Russo I, et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:2215-21
157. Etgen GJ, Fryburg DA, Gibbs EM. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction - and phosphatidylinositol-3- kinase-independent pathway. Diabetes 1997;46:1915-9
158. Tanaka T, Nakatani K, Morioka K, et al. Nitric oxide stimulates glucose transport through insulin-independent GLUT4 translocation in 3T3-L1 adipocytes. Eur J Endocrinol 2003;149:61-7
159. Fryer LGD, Hajduch E, Rencurel F, et al. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes 2000;49:1978-85
160. Punkt K, Naupert A, Wellner M, Asmussen G, Schmidt C, Buchwalow IB. Nitric oxide synthase II in rat skeletal muscles. Histochem Cell Biol 2002;118:371-9
161. Pilon G, Penfornis P, Marette A. Nitric oxide production by adipocytes: a role in the pathogenesis of insulin resistance? Horm Metab Res 2000;31:480-4
162. Schmid E, Hotz-Wagenblatt A, Dröge W. Inhibition of the insulin receptor kinase phosphorylation by nitric oxide: functional and structural aspects. Antioxid Redox Signal 1999;1:45-53
163. Lawler JM, Song W. Specificity of antioxidant enzyme inhibition in skeletal muscle to reactive nitrogen species donors. Biochem Biophys Res Commun 2002;294:1093-100
164. Cellek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus -a nitric oxide-dependent phenomenon. Br J Pharmacol 1999128:1804-12
165. Almeida A, Moncada S, Bolanos JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol 2004;6:45-51
166. Poon BY, Raharjo E, Patel K, et al. Complexity of inducible nitric oxide synthase. Cellular source determines benefit versus toxicity. Circulation 2003;108:1107-12
167. Carey PE, Halliday J, Snaar JEM, Morris PG, Taylor R. Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects. Am J Physiol Endocrinol Metab 2003;284: E688-94
168. Mandarino LJ, Consoli A, Jain A, Kelley DE. Differential regulation of intracellular glucose metabolism by glucose and insulin in human muscle. Am J Physiol 1993;265:E898-905
169. Vaag A, Damsbo P, Hother-Nielsen O, Beck-Nielsen H. Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:80-8
170. Ortmeyer HK, Bodkin NL, Varhese SS, Hansen BC. Glycogen phosphorylase activity and glycogen concentration in muscle of normal to overtly diabetic rhesus monkeys. Int J Obes Relat Metab Disord 1996; 20:98-105
171. Levin K, Saa Schroeder H, Alford FP, Beck-Nielsen H. Morphometric documentation of abnormal intramyocellular fat storage and reduced glycogen in obese patients with Type II diabetes. Diabetologia 2001;44:824-33
172. Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 1991;87:489-95
173. Derave W, Hansen BF, Lund S, Kristiansen S, Richter EA. Muscle glycogen content affects insulin-stimulated glucose transport and protein kinase B activity. Am J Physiol Endocrinol Metab 2000;279: E947-55
174. Muller C, Assimacopoulos-Jeannet F, Mosimann F, et al. Endogenous glucose production, gluconeogenesis and liver glycogen concentration in obese non-diabetic patients. Diabetologia 1997;40:463-8
175. Henriksen EJ, Kinnick TR, Teachey MK, et al. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 2003;bng 284:E892-900
176. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002;8:126-32
177. Nikoulina SE, Ciaraldi THP, Mudaliar S, Carter L, Jonson K, Henry RR. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002;51: 2190-8
178. Chen X, McMahon EG, Gulve EA. Stimulatory effect of lithium on glucose transport in rat adipocytes is not mediated by elevation of IP1. Am J Physiol 1998;275:E272-7
179. Tabata I, Schluter J, Gulve EA, Holloszy JO. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes 1994;43:903-7
180. Oreña SJ, Torchia AJ, Garofalo RS. Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 2000;275:15765-72
181. Fisher JS, Nolte LA, Kawanaka K, Han KH, Jones TE, Holloszy JO. Glucose transport rate and glycogen synthase activity both limit skeletal muscle glycogen accumulation. Am J Physiol Endocrinol Metab 2002;282:E1214-21
182. m) in human muscle cells depends on the COOH-terminal region and glycogen content. Diabetes 2003;52:2221-6
183. Baqué S, Montell E, Guinovart JJ, Newgard CB, Gomez-Foix A. Expression of glucokinase in cultured human muscle cells confers insulin-independent and glucose concentration-dependent increases in glucose disposal and storage. Diabetes 1998;47:1392-8
184. Otaegui PJ, Ontiveros M, Ferre T, Riu E, Jiménez R, Bosch F. Glucose-regulated glucose uptake by transplanted muscle cells expressing glucokinase counteracts diabetic hyperglycemia. Hum Gene Ther 2002;13:2125-33
185. Manchester J, Skurat AV, Roach P, Hauschka SD. Increased glycogen accumulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. Proc Nad Acad Sci USA 1996;93:10707-11
186. Richter EA, Hansen SA, Hansen BF. Mechanisms limiting glycogen storage in muscle during prolonged insulin stimulation. Am J Physiol 1988;255:E621-8
187. Hansen BF, Asp S, Kiens B, Richter EA. Glycogen concentration in human skeletal muscle: effect of prolonged insulin and glucose infusion. Scand J Med Sci Sports 1999;9:209-13